科研项目：
2024年国家自然科学基金委员会青年科学基金项目（C类），2025-2027，主持
代表性文章：
(1)Zhu, F. 1; Wang, J. 1; Ryan, C. E.; Hackett, L.; Zhang, J.; Chamberlain, S.; Ung, J.; Chong, S. J. F.; Davids, M. S. Inhibition of PRMT5 Sensitizes B-Cell Non-Hodgkin Lymphoma Cells to Both Intrinsic and Extrinsic Apoptotic Cell Death. Blood Neoplasia 2026, 3 (3), 100249. https://doi.org/10.1016/j.bneo.2026.100249
(2)Zhu, F. 1; Crombie, J. L.; Ni, W.; Hoang, N.-M.; Garg, S.; Hackett, L.; Chong, S. J. F.; Collins, M. C.; Rui, L.; Griffin, J.; Davids, M. S. Hypomethylating Agent Decitabine Sensitizes Diffuse Large B-Cell Lymphoma to Venetoclax. Haematologica 2023. https://doi.org/10.3324/haematol.2023.283245
(3)Zhu, F. 1; Guo, H.; Bates, P. D.; Zhang, S.; Zhang, H.; Nomie, K. J.; Li, Y.; Lu, L.; Seibold, K. R.; Wang, F.; Rumball, I.; Cameron, H.; Hoang, N. M.; Yang, D. T.; Xu, W.; Zhang, L.; Wang, M.; Capitini, C. M.; Rui, L. PRMT5 Is Upregulated by B-Cell Receptor Signaling and Forms a Positive-Feedback Loop with PI3K/AKT in Lymphoma Cells. Leukemia 2019, 33 (12), 2898–2911. https://doi.org/10.1038/s41375-019-0489-6
(4)Lu, L.1; Zhu, F. 1; Zhang, M.; Li, Y.; Drennan, A. C.; Kimpara, S.; Rumball, I.; Selzer, C.; Cameron, H.; Kellicut, A.; Kelm, A.; Wang, F.; Waldmann, T. A.; Rui, L. Gene Regulation and Suppression of Type I Interferon Signaling by STAT3 in Diffuse Large B Cell Lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2018, 115 (3), E498–E505. https://doi.org/10.1073/pnas.1715118115
(5)Zhu, F. 1; Rui, L. PRMT5 in Gene Regulation and Hematologic Malignancies. Genes Dis. 2019, 6 (3), 247–257. https://doi.org/10.1016/j.gendis.2019.06.002
(6)Zhu, F. 1; Wang, K. B.; Rui, L. STAT3 Activation and Oncogenesis in Lymphoma. Cancers 2019, 12 (1), 19. https://doi.org/10.3390/cancers12010019
(7)Zhu, F. 1; Hwang, B.; Miyamoto, S.; Rui, L. Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-Cell Lymphoma. Mol. Cancer Res. MCR 2017, 15 (3), 348–357. https://doi.org/10.1158/1541-7786.MCR-16-0344
(8)Liu, Y.; Chen, R.; Gao, X.; Zhu, F.; Ni, Q.; Bates, P. D.; Wu, S.; Zai, Z.; Obernberger, V. A.; Weerawardhene, K.; Tourdot, T. K.; Petta, S.; Conyers, M. J.; Capitini, C. M.; Rui, L. PRMT5 Inhibition Sensitizes B-Cell Lymphoma Cells to Ferroptosis. Leukemia 2026. https://doi.org/10.1038/s41375-026-02932-3
(9)Chong, S. J. F.; Zhu, F.; Dashevsky, O.; Mizuno, R.; Lai, J. X. H.; Hackett, L.; Ryan, C. E.; Collins, M. C.; Iorgulescu, J. B.; Guièze, R.; Penailillo, J.; Carrasco, R.; Hwang, Y. C.; Muñoz, D. P.; Bouhaddou, M.; Lim, Y. C.; Wu, C. J.; Allan, J. N.; Furman, R. R.; Goh, B. C.; Pervaiz, S.; Coppé, J.-P.; Mitsiades, C. S.; Davids, M. S. Hyperphosphorylation of BCL-2 Family Proteins Underlies Functional Resistance to Venetoclax in Lymphoid Malignancies. J. Clin. Invest. 2023, 133 (22). https://doi.org/10.1172/JCI170169
(10)Hoang, N.-M.; Liu, Y.; Bates, P. D.; Heaton, A. R.; Lopez, A. F.; Liu, P.; Zhu, F.; Chen, R.; Kondapelli, A.; Zhang, X.; Selberg, P. E.; Ngo, V. N.; Skala, M. C.; Capitini, C. M.; Rui, L. Targeting DNMT3A-Mediated Oxidative Phosphorylation to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Cell Rep. Med. 2024, 5 (4). https://doi.org/10.1016/j.xcrm.2024.101484
(11)Kimpara, S.; Lu, L.; Hoang, N. M.; Zhu, F.; Bates, P. D.; Daenthanasanmak, A.; Zhang, S.; Yang, D. T.; Kelm, A.; Liu, Y.; Li, Y.; Rosiejka, A.; Kondapelli, A.; Bebel, S.; Chen, M.; Waldmann, T. A.; Capitini, C. M.; Rui, L. EGR1 Addiction in Diffuse Large B-Cell Lymphoma. Mol. Cancer Res. 2021, 19 (8), 1258–1269. https://doi.org/10.1158/1541-7786.MCR-21-0267
(12)Masle-Farquhar, E.; Russell, A.; Li, Y.; Zhu, F.; Rui, L.; Brink, R.; Goodnow, C. C. Loss-of-Function of Fbxo10, Encoding a Post-Translational Regulator of BCL2 in Lymphomas, Has No Discernible Effect on BCL2 or B Lymphocyte Accumulation in Mice. PLOS ONE 2021, 16 (4), e0237830. https://doi.org/10.1371/journal.pone.0237830
